Volume 19, Issue 1 pp. 80-90

How many cisplatin administration protocols does your department use?

A.P. GREYSTOKE bsc, mbchb, mrcp, registrar medical oncology

A.P. GREYSTOKE bsc, mbchb, mrcp, registrar medical oncology

Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland, UK

Search for more papers by this author
D.I. JODRELL dm, msc, frcpe, professor of cancer therapeutics

D.I. JODRELL dm, msc, frcpe, professor of cancer therapeutics

Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland, and University of Edinburgh, Scotland

Search for more papers by this author
M. CHEUNG msc, mrpharms, oncology pharmacist

M. CHEUNG msc, mrpharms, oncology pharmacist

Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland, UK

Search for more papers by this author
I. RIVANS mrpharms pgdip, oncology pharmacist

I. RIVANS mrpharms pgdip, oncology pharmacist

Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland, UK

Search for more papers by this author
M.J. MACKEAN mbchb, msc, mrcp, md, consultant medical oncologist

Corresponding Author

M.J. MACKEAN mbchb, msc, mrcp, md, consultant medical oncologist

Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland, UK

Melanie Mackean, Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland EH4 2XU, UK (e-mail: [email protected]). Search for more papers by this author
First published: 21 December 2009
Citations: 12

This work did not require any financial support and was undertaken as part of the ongoing audit process in the Edinburgh Cancer Centre.

Abstract

GREYSTOKE A.P., JODRELL D.I., CHEUNG M., RIVANS I. & MACKEAN M.J. (2009) European Journal of Cancer Care19, 80–90
How many cisplatin administration protocols does your department use?

The introduction, 30 years ago, of the co-administration of appropriate hydration and ensuring a diuresis occurs during the administration of cisplatin was important in its development, allowing clinically significant doses to be given with acceptable rates of toxicity. The clinical usage of cisplatin has increased and hydration protocols have been amended to increase patient comfort and reduce resource utilization. We suspected that this had led to unnecessary variations in practice both in clinical trials and subsequently in the clinic. Therefore, we reviewed practice in the Edinburgh Cancer Centre and discovered that 25 different hydration protocols were in use, with wide variation in dilution of cisplatin, total fluid administered, use of electrolyte (potassium and magnesium) supplementation and diuretics. These differences are a reflection of adoption of variations in hydration regimes published in pivotal clinical trials. A review of the available evidence relating to cisplatin associated hydration regimens was performed and recommendations will be made for the future design of evidence-based protocols.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.